

## Lipum AB (publ) informs that Flerie Invest AB has passed the threshold for a mandatory bid

Lipum AB's (publ) ("Lipum") main owner Flerie Invest AB ("Flerie") announced on 1 March 2024 that it has acquired an additional 859 shares in Lipum and that Flerie thereafter owns a total of 2,981,553 shares, corresponding to approximately 32.01 per cent of the total number of shares and votes in Lipum.

According to the Swedish Securities Council's statement AMN 2023:30, Flerie was granted an exemption from the obligation to make a mandatory bid that could arise as a result of Flerie subscribing for its pro rata share in the rights issue that Lipum carried out in 2023. According to the exemption, an obligation to make a mandatory bid arises if Flerie subsequently acquires additional shares and thereby increases its voting rights in Lipum.

Thereby, the threshold for a mandatory bid according to the Takeover rules for certain trading platforms has been exceeded. According to Flerie's press release, Flerie intends to revert with information about a possible public takeover bid for the remaining shares in Lipum within four weeks from 1 March 2024.

For further information, please refer to Flerie's press release, [Flerie Invest AB has increased its holding in Lipum AB \(publ\), whereby the limit for mandatory bidding has been exceeded – Flerie](#).

### Contacts

Ola Sandborgh, CEO

[ola.sandborgh@lipum.se](mailto:ola.sandborgh@lipum.se)

+46 72 218 80 21

Web: [www.lipum.se](http://www.lipum.se)

### About Us

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

**PRESS RELEASE**

04 March 2024 08:00:00 CET



**Attachments**

[Lipum AB \(publ\) informs that Flerie Invest AB has passed the threshold for a mandatory bid](#)